Alzheimer's Disease Drug Development

Jeffrey Cummings, MD, ScD, is Director of the Chambers-Grundy Center for Transformative Neuroscience at University of Nevada, Las Vegas. He is an expert clinical trialist and leading figure in drug development for Alzheimer's Disease including, disease-modifying agents, cognitive enhancing drugs, and treatments for neuropsychiatric symptoms. He has broad interests in therapeutic innovation, neuroscience, and the intersection of science, policy, and society. Dr. Cummings was Founding Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA; Founder and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA; and Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Jefferson Kinney, PhD, is the Founder and Reg Grundy and Joy Chambers-Grundy Chair of the Department of Brain Health at the University of Nevada, Las Vegas. Research projects in Dr. Kinney's laboratory focus on the investigation of cellular and molecular mechanisms altered in pre-clinical models of Alzheimer's Disease, with particular emphasis on neuronal and glia interactions and the investigation of novel therapeutic targets. Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation, is an internationally recognized geriatrician, neuroscientist, expert in Alzheimer's Disease, and an innovative philanthropy executive. Dr. Fillit has had a distinguished academic medicine career and is currently a clinical professor of geriatric medicine and palliative care, medicine, and neurosciences at the Icahn School of Medicine at Mount Sinai in New York.

'The book occupies a unique niche among similar titles in the area, presenting the state-of-the-art in Alzheimer's disease drug development from a drug discovery perspective, a clinical perspective, and a financial perspective.' Marc A. Ilies, Doody's Review

• Part I. Advancing Alzheimer therapies in a collaborative science ecosystem; Part II. Non-Clinical assessment of Alzheimer candidate drugs; Part III. Alzheimer clinical trials; Part IV. Imaging and biomarker development in Alzheimer drug discovery; Part V. Academic drug development programs; Part VI. Public-Private partnerships in Alzheimer drug development; Part VII. Funding and financing Alzheimer drug development.